Background and Purpose-Whether to resume oral anticoagulation treatment after intracerebral hemorrhage (ICH) remains an unresolved question. Previous studies focused primarily on recurrent stroke after ICH. We sought to investigate the association between cardioembolic stroke risk, oral anticoagulation therapy resumption, and functional recovery among ICH survivors in the absence of recurrent stroke. Methods-We conducted a joint analysis of 3 observational studies: (1) the multicenter RETRACE study (GermanWide Multicenter Analysis of Oral Anticoagulation Associated Intracerebral Hemorrhage); (2) the Massachusetts General Hospital ICH study (n=166); and (3) the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage; n=131). We included 941 survivors of ICH in the setting of active oral anticoagulation therapy for prevention of cardioembolic stroke because of nonvalvular atrial fibrillation and without evidence of ischemic stroke and recurrent ICH at 1 year from the index event. We created univariable and multivariable models to explore associations between cardioembolic stroke risk (based on CHA 2 DS 2 -VASc scores) and functional recovery after ICH, defined as achieving modified Rankin Scale score of ≤3 at 1 year for participants with modified Rankin Scale score of >3 at discharge. Results-In multivariable analyses, the CHA 2 DS 2 -VASc score was associated with a decreased likelihood of functional recovery (odds ratio, 0.83 per 1 point increase; 95% CI, 0.79-0.86) at 1 year. Anticoagulation resumption was independently associated with a higher likelihood of recovery, regardless of CHA 2 DS 2 -VASc score (odds ratio, 1.89; 95% CI, 1.32-2.70). We found an interaction between CHA 2 DS 2 -VASc score and anticoagulation resumption in terms of association with increased likelihood of functional recovery (interaction P=0.011). Conclusions-Increasing cardioembolic stroke risk is associated with a decreased likelihood of functional recovery at 1 year after ICH, but this association was weaker among participants resuming oral anticoagulation therapy. These findings support, including recovery metrics, in future studies of anticoagulation resumption after ICH.
I
ntracerebral hemorrhage (ICH) is the most severe and least treatable form of stroke. ICH accounts for 10% to 20% of all acute cerebrovascular events and are responsible for ≈50% of stroke-related disability and mortality. 1, 2 Oral anticoagulation treatment (OAT) is associated with increased ICH risk, with ≈80% of cases occurring during treatment of underlying atrial fibrillation aimed at preventing cardioembolic stroke. 3, 4 Thus, resuming OAT is a major clinical dilemma in ICH care because the increased risk of recurrent bleeding must be weighed against the beneficial protection from thromboembolic events. 5, 6 Previous observational studies have associated OAT resumption with decreased mortality and decreased ischemic stroke risk after OAT-related ICH, as confirmed in a recent meta-analysis of all available data. [7] [8] [9] [10] [11] [12] [13] OAT resumption was recently found to be associated with improved functional outcome at 1-year post-ICH, likely reflecting the aforementioned reduction in symptomatic ischemic stroke risk.
14 However, atrial fibrillation has also been associated with increased incidence of asymptomatic (ie, subclinical) ischemic strokes. 15, 16 These covert ischemic events may negatively impact outcome after OAT-ICH, even in the absence of clinical symptomatology. 17 Prevention of asymptomatic infarcts could, therefore, represent an additional mechanism linking cardioembolic stroke risk, OAT resumption and post-ICH outcome.
We, therefore, sought to determine: (1) whether cardioembolic stroke risk (as defined by CHA 2 DS 2 -VASc scores) is associated with recovery after OAT-ICH, even in the absence of recurrent stroke and (2) whether OAT resumption alters the association between cardioembolic stroke risk and recovery after OAT-ICH. To test these hypotheses, we collected and analyzed individual-level data from 3 large studies of ICH: (1) the multicenter RETRACE study (German-Wide Multicenter Analysis of Oral Anticoagulation Associated Intracerebral Hemorrhage) of OAT-ICH in Germany; (2) a single-center longitudinal study of ICH conducted in Boston; and (3) the United States based multicenter ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage). 7, 18, 19 This large collaborative effort allowed us to analyze individual-level data for consecutive OAT-ICH cases.
Methods

Data, Materials, and Code Disclosure Statement
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Design and Participating Studies
We present results of data collected by 3 prospective studies of OATrelated ICH: (1) the multicenter RETRACE study, coordinated by the University of Erlangen-Nuremberg (Erlangen, Germany) and conducted from 2006 to 2010 in 19 tertiary care centers across Germany 7 ; (2) the Massachusetts General Hospital (MGH) single-center longitudinal study of ICH conducted in Boston, since 1994 and currently ongoing 18 ; and (3) the multicenter ERICH study, coordinated by the University of Cincinnati (Cincinnati, OH) and enrolling ICH cases and controls from 2011 to 2015 at 19 clinical recruitment centers across the United States. 19 Because MGH participated as a recruitment center for the ERICH study, ERICH participants enrolled at MGH were only included in the ERICH analyses, to avoid data duplication.
Participant Enrollment and Baseline Data Acquisition
Eligible participants were (1) diagnosed with primary ICH (confirmed on computed tomography scan); (2) age 18 years or older at time of ICH; (3) without history of prior ICH (before the index event at enrollment); (4) without history of functional impairment and dependence before ICH; (5) on active OAT for prevention of cardioembolic stroke because of previously diagnosed nonvalvular atrial fibrillation at time of ICH; (6) alive and eligible for potential OAT resumption (ie, with care not focused on comfort measures only) at time of discharge from acute care; and (7) not diagnosed with recurrent ICH or ischemic stroke at 1-year follow-up. 7, 14, 18, 19 Informed consent for participation in each individual study (including data sharing) was obtained from all participants or their legally designated surrogates. For the purpose of these analyses, OAT resumption was defined as active use of Vitamin K antagonists agents, according to previously published criteria.
14 Data on demographics, medical history, pre-ICH medication exposures, and laboratory results were obtained via structured interview of patients and informants at time of enrollment. 7, 14, 18, 19 We supplemented information obtained in-person via review of available medical records at each individual institution. Medical records were also reviewed to determine functional status at discharge (defined as modified Rankin Scale [mRS]). Available information was used to compute values for the CHA 2 DS 2 -VASc score. 7, 18, 19 Of note, ICH was not considered a stroke for the purpose of calculating CHA 2 DS 2 -VASc scores.
14 Institutional Review Boards or Ethical Committees reviewed and approved all study protocols.
Longitudinal Follow-up
Follow-up information was obtained via phone interviews, aimed at identifying (1) OAT resumption status; (2) mortality; (3) mRS captured using the simplified mRS questionnaire 20 ; and (4) recurrent stroke events, including both recurrent ICH and ischemic stroke. 7, 14, 18, 19 All follow-up phone interviews and outcome adjudications were conducted by the coordinating center for each of the participating studies. OAT resumption was defined in an identical manner as for eligibility criteria listed above. Interviews were conducted at 3 months, 6 months, and 1 year from index ICH, based on established protocols. [17] [18] [19] Patient-derived follow-up information was corroborated by review of pertinent medical records.
Statistical Methods
Overall Analysis Framework
Given the heterogeneity in design and recruitment procedures across participating studies, we used a meta-analysis framework to compile results from individual datasets. 14, 21 This approach allows for formal exploration of effect heterogeneity using validated statistical tools. 22 We initially conducted separate univariable and multivariable analyses (see below) for the RETRACE, MGH-ICH, and ERICH studies. Results from multivariable analyses from each individual study were then metaanalyzed using a conservative inverse variance-based random effects method (DerSimonian-Laird). 21 Cochran Q test was used to estimate heterogeneity, followed by calculation of I 2 . 22 Effect size heterogeneity was considered significant for heterogeneity P values <0.10 or I 2 >0.20.
Variables' Definition and Handling
We defined recovery in functional status based on the difference in mRS scores at 1-year post-ICH versus discharge from acute care. We used 2 different definitions of post-ICH recovery: (1) functional recovery, that is transition to mRS score of ≤3 at 1 year after ICH among those with mRS score of >3 at discharge and (2) mRS score change during follow-up, with positive values indicating increasing mRS over time, and negative numbers indicating decreasing mRS (ie, recovery). We also conducted the following secondary analyses: (1) including participants experiencing recurrent ICH (n=18) and (2) repeating all analyses after exclusion of individuals experiencing death during follow-up because some deaths may have been caused by nondiagnosed strokes.
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Univariable and Multivariable Models
Categorical variables were compared using Fisher exact test (2-tailed) and continuous variables using the Mann-Whitney rank-sum or unpaired t test. Multivariable analyses utilized logistic regression or ordinal logistic regression. We initially included in multivariable modeling all factors associated with outcomes of interest in univariable analyses with P<0.20. All variables included in the CHA 2 DS 2 -VASc score (eg, age) were only entered as part of the score itself, to avoid likely multicollinearity issues. We subsequently used backward elimination procedures to arrive at a minimal model, including only variables associated with functional recovery or with OAT resumption status at P<0.05. We initially conducted interaction analyses between the CHA 2 DS 2 -VASc score and OAT resumption using interaction terms in multivariable analyses. We subsequently repeated multivariable analyses within strata defined by CHA 2 DS 2 -VASc scores (0-2, 3-4, 5-6, and 7-9) to approximately subdivide participants in equal-sized groups. We conducted model diagnostics including (1) testing the proportional odds assumption (Brant test); (2) evaluation of multicollinearity via variable input function calculation (prespecified removal of variables with variable input function ≥3, none qualified); (3) visual inspection of residual versus fitted value plots; and (4) goodness of fit evaluation via the Hosmer-Lemeshow test. For all analyses, we considered P values <0.05 (2-tailed) statistically significant, after adjustment for multiple testing using the false discovery rate method. 23 All analyses were performed with R v3.4.4 (the R Project for Statistical Computing), including the car, generalhoslem, brant, and meta-packages.
Results
Study Participants
After application of inclusion and exclusion criteria, we analyzed data for 941 OAT-ICH survivors (Figure 1 ). Participants' characteristics are presented in Table 1 . OAT resumption rate was lower in the ERICH study (20%) compared with the RETRACE (29%) and MGH-ICH (33%) studies (P<0.05 for both comparisons). All other medical history characteristics (including CHA 2 DS 2 -VASc score) did not differ among studies (all P>0. 20) . A total of 262/941 (29%) OAT-ICH survivors resumed oral anticoagulation during follow-up. Median time to OAT resumption was 32 days (interquartile range, 24-65). In univariable analyses ICH location, antiplatelet use during follow-up and CHA 2 DS 2 -VASc score were the only patient characteristics associated with OAT resumption status ( Table 2 ). Detailed information on patient characteristics by OAT resumption status and study are presented in Table I in the online-only Data Supplement. Multivariable analyses confirmed that higher CHA 2 DS 2 -VASc scores were associated with OAT resumption (odds ratio [OR], 1.74; 95% CI, 
Cardioembolic Risk and Functional Recovery After OAT-ICH
We first sought to examine the association between cardioembolic stroke risk and functional recovery 1 year after OAT-ICH in univariable analyses. We found that increasing cardioembolic stroke risk (ie, higher CHA 2 DS 2 -VASc score) was associated with decreased likelihood of functional recovery at 1 year (Fisher exact P<0.001 for all combined data) and with change in mRS score over time (P<0.001 for all combined data). Among other variables listed in Table 1 , only discharge mRS was also associated with likelihood of functional recovery and mRS change over time (both P<0.001 for all combined data).
Multivariable analyses (Table 3) confirmed that the CHA 2 DS 2 -VASc score was associated with both functional recovery and mRS score change at 1 year after ICH. On restricting our analyses to participants who did not experience death during follow-up (n=614; Figure 1 
OAT Resumption and Functional Recovery After OAT-ICH
In univariable analyses, OAT resumption was associated with functional recovery at 1 year (Fisher exact P<0.001 for all combined data) and with mRS score change over time (P<0.001 for all combined data). Multivariable analyses confirmed that OAT resumption was independently associated with higher likelihood of functional recovery and mRS decrease at 1 year after ICH, regardless of CHA 2 DS 2 -VASc score (Table 3 ). We present the combined effects of the CHA 2 DS 2 -VASc score and OAT resumption on functional recovery after ICH in Figure 2 . On restricting our analyses to individuals who did not experience mortality during follow-up, we found that OAT resumption was still associated with increased likelihood of functional recovery (OR, All analyses adjusted for discharge modified Rankin Scale, ICH location, and exposure to antiplatelet agents. ERICH indicates Ethnic/Racial Variations of Intracerebral Hemorrhage; ICH, intracerebral hemorrhage; MGH, Massachusetts General Hospital; mRS, modified Rankin Scale; OAT, oral anticoagulation treatment; OR, odds ratio; and RETRACE, German-Wide Multicenter Analysis of Oral Anticoagulation Associated Intracerebral Hemorrhage.
*Defined as achieving mRS ≤3 if mRS >3 at discharge. †Difference in mRS score between 1-y follow-up and discharge, effect size calculated for 1 point decrease in mRS.
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Supplement). CHA 2 DS 2 -VASc score and OAT resumption showed an interaction in associating with likelihood of functional recovery (interaction P=0.011) and mRS decrease (P=0.012) at 1 year after ICH. This resulted in participants with higher CHA 2 DS 2 -VASc score demonstrating larger effect sizes for the association between OAT resumption and functional recovery. This observation was confirmed by conducting analyses of association between OAT resumption and functional recovery after stratification by CHA 2 DS 2 -VASc score (Table 4) .
Discussion
We present evidence from combined analyses of 3 large observational studies, identifying associations between higher cardioembolic stroke risk and lower likelihood of functional recovery at 1 year after ICH, in the absence of recurrent ICH or ischemic stroke. We also demonstrated that OAT resumption lowered the effect size of associations between cardioembolic stroke risk and functional recovery at 1-year post-ICH. These findings indicate that cardioembolic stroke risk may play a negative role in recovery after ICH, thus adding an additional target end point for future studies of OAT resumption after primary ICH. Cardioembolic stroke risk and oral anticoagulation resumption are expected to influence recovery after OAT-ICH by affecting ischemic stroke rate, with associated additional disability.
14 To focus on potential associations with functional recovery, we limited our analysis to individuals who did not experience recurrent ICH or subsequent ischemic stroke. It is possible that less severe embolic infarcts are not causing clinically evident deficits may have resulted in enough central nervous system damage to hinder post-ICH recovery. Atrial fibrillation is associated with a hypercoagulable state, and up to 30% of patients with atrial fibrillation demonstrated evidence of micro embolism via transcranial Doppler ultrasonography. [24] [25] [26] These observations point to the most likely mechanism linking atrial fibrillation with covert infarcts, that is occult cardioembolism. 15 Of note, previous studies on ischemic stroke associated with atrial fibrillation also uncovered associations between embolic stroke risk and outcome. 17 Because of the lack of surveillance imaging, we are unfortunately unable to further test this hypothesis in our study. Atrial fibrillation has also been associated with cognitive impairment (especially in terms of memory performance), even among stroke-free patients. 15 Previous studies clarified that ICH survivors are at high risk for dementia 27, 28 ; atrial fibrillation may further increase risk for cognitive impairment, in itself a major obstacle to rehabilitation and recovery after stroke. 29 Several additional biological observations can also be invoked to account for our findings, including decreased cerebral perfusion (as a result of reduced cardiac output) and proinflammatory state because of atrial fibrillation. 30 Finally, increasing CHA 2 DS 2 -VASc scores may represent an increasing burden of comorbid conditions negatively affecting post-ICH recovery. However, we identified an interaction between cardioembolic stroke risk and OAT resumption, suggesting that embolic risk (influenced by OAT resumption) is likely to be central to the association between CHA 2 DS 2 -VASc scores and functional outcome.
Our study has several limitations. First and foremost, the observational nature of the participating studies implies the potential for confounding bias (especially severity and indication bias). Lack of randomization in OAT resumption may have led to preferential assignment to anticoagulation of patients at higher likelihood to experience functional recovery to begin with. However, our findings suggest that individuals with higher CHA 2 DS 2 -VASc scores were more likely to resume OAT. As these individuals were also shown to be less likely to achieve functional recovery, one would expect OAT resumption to also be associated with worse post-ICH outcome. On the contrary, individuals with higher CHA 2 DS 2 -VASc scores (especially those restarted on OAT) may also have more healthcare resources devoted to their recovery by dint of their high-risk status and comorbidity burden, thus leading to residual confounding influencing our analyses. Ultimately, only a randomized clinical trial of OAT resumption after ICH (ideally including serial MRI imaging of silent infarcts) would provide definitive validation of our findings. Additionally, we opted to exclude patients with atrial fibrillation who experienced ICH without OAT exposure, because they are unlikely to start OAT after ICH (usually because of low cardioembolic stroke risk), and, therefore, would add limited power to test our main hypotheses. Our study also displays several notable strengths. Thanks to a large collaborative effort, we gathered individual-level data for a large number of OAT-ICH survivors, with in-depth capture of baseline and follow-up outcome information. Several recent studies explored the risk and benefits of OAT resumption after primary ICH. [7] [8] [9] [10] [11] However, none explored the association with functional outcome, and whether oral anticoagulation modifies this association. We also gathered OAT-ICH cases from a variety of clinical settings (tertiary care academic centers, community-based academic hospitals, and community institutions), thus greatly enhancing the generalizability of our findings. Finally, we demonstrated consistent findings across all 3 included studies.
Overall, our findings strongly support including recovery metrics in the design of randomized clinical trials of anticoagulation resumption after OAT-ICH. Additionally, future studies aimed at assessing the potential role of covert cardioembolic events (eg, via surveillance neuroimaging) are warranted to better elucidate the pathophysiology of recovery after OAT-ICH. Finally, future studies should explore the association between cardioembolic risk, OAT resumption and long-term outcomes in multiple functional domains, including motor and cognitive recovery.
Summary
In conclusion, we present evidence from a large collaborative effort identifying novel associations between cardioembolic stroke risk and functional recovery after OAT-related ICH. We also found evidence that these associations are weaker among individuals resuming oral anticoagulation, especially those with the highest cardioembolic stroke risk. Randomized clinical trials are needed to more accurately guide optimal decision making on All analyses adjusted for discharge modified Rankin Scale, ICH location, and exposure to antiplatelet agents. ICH indicates intracerebral hemorrhage; mRS, modified Rankin Scale; OAT, oral anticoagulation treatment; and OR, odds ratio.
Stroke
resuming OAT for these patients and their healthcare providers. Ideally, these future studies will benefit from including detailed recovery metrics among post-ICH outcomes of interest.
